Total lymphocyte count: Not a surrogate marker for risk of death in HIV-infected Ugandan children

Journal of Acquired Immune Deficiency Syndromes

Volumn 49, Issue 2, 2008, Pages 171-178

  Musoke, Philippa M ^a   Young, Alicia M ^b   Owor, Maxensia A ^a   Lubega, Irene R ^a   Brown, Elizabeth R ^b,c   Mmiro, Francis A ^a   Mofenson, Lynne M ^d   Jackson, J Brooks ^e   Fowler, Mary Glenn ^e   Guay, Laura A ^e  

^a MAKERERE UNIVERSITY   (Uganda)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^e DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Africa; Children; HIV; Total lymphocyte count

Indexed keywords

ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PEDIATRICS; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK; UGANDA; IMMUNOLOGY; LONGITUDINAL STUDY; NEWBORN; PROGNOSIS;

BIOLOGICAL MARKER;

BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; CHILD, PRESCHOOL; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; LONGITUDINAL STUDIES; LYMPHOCYTE COUNT; PROGNOSIS; RETROSPECTIVE STUDIES; UGANDA;

EID: 55249109363     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318183a92a     Document Type: Article

References (32)

1. UNAIDS/WHO 2006 Report on the Global AIDS Epidemic. Available at: http://www.unaids.org/en/HIV/data. Accessed September 29, 2006.
2. Newell ML, Brahmbhatt H, Ghys PD. Child mortality and HIV infection in Africa: a review. AIDS. 2004;18(Suppl 2):S27-S34.
3. Obimbo EM, Mbori-Ngacha DA, Ochieng JO, et al. Predictors of early mortality in a cohort of human immunodeficiency virus type 1-infected African children. Pediatr Infect Dis J. 2004;23:536-543.
4. Mofenson LM, Harris DR, Moye J, et al. Alternatives to HIV-1 RNA concentration and CD4 count to predict mortality in HIV infected children in resource-poor settings. Lancet. 2003;362:1625-1627.
5. Palumbo PE, Raskino C, Fiscus S, et al. Predictive value of quantitative plasma HIV RNA and CD4 lymphocyte count in HIV infected infants and children. JAMA. 1998;279:756-761.
6. Taha TE, Kumwenda NI, Hoover DR, et al. Association of HIV-1 load and CD4 lymphocyte count with mortality among untreated African children over one year of age. AIDS. 2000;14:453-459.
7. Guay L, Horn D, Kabengera S, et al. HIV-1 ICD p24 antigen detection in Ugandan infants: use in early diagnosis of infection and a marker of disease progression. J Med Virol. 2000;62:426-434.
8. Badri M, Wood R. Usefulness of total lymphocyte count in monitoring highly active antiretroviral therapy in resource-limited settings. AIDS. 2003;17:541-545.
9. Post FA, Wood R, Maartens G. CD4 and total, lymphocyte counts as predictors of HIV disease progression. QJM. 1996;89:505-508.
10. Spacek LA, Griswold M, Quinn TC, et al. Total lymphocyte count and hemoglobin combined in an algorithm to initiate the use of highly active antiretroviral therapy in resource-limited settings. AIDS. 2003;17:13111317.
11. Mekonnen Y, Dukers NH, Sanders E, et al. Simple markers for initiating antiretroviral therapy among HIV-infected Ethiopians. AIDS. 2003; 17: 815-819.
12. Schreibman T, Friedland G. Use of total lymphocyte count for monitoring response to antiretroviral therapy. Clin Infect Dis. 2004;38:257-262.
13. Akinola NO, Olasode O, Adediran IA, et al. The search for a predictor of CD4 cell count continues: total lymphocyte count is not a substitute for CD4 cell count in the management of HIV-infected individuals in a resource-limited setting. Clin Infect Dis. 2004;39:579-581.
14. Bedell. R, Heath KV, Hogg RS, et al. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral, therapy among HIV-infected individuals in resource-limited settings. Antivir Ther. 2003;8:379-384.
15. Mwamburi DM, Ghosh M, Fauntleroy J, et al. Predicting CD4 count using total lymphocyte count: a sustainable tool for clinical decisions during HAART use. Am J Trop Med Hyg. 2005;73:58-62.
16. Kumarasamy N, Mahajan AP, Flanigan TP, et al. Total lymphocyte count (TLC) is a useful tool for the timing of opportunistic infection prophylaxis in India and other resource-constrained settings. J Acquir Immune Defic Syndr. 2002;31:378-383.
17. Stebbing J, Sawleshwarkar S, Michailidis C, et al. Assessment of the total lymphocyte counts as predictors of AIDS defining infections in HIV infected people. Postgrad Med J. 2005;81:586-588.
18. Antiretroviral therapy of HIV infection in infants and children in resourcelimited settings. WHO Guidelines. Available at: http://www.who.int/hiv/ pub/guidelines. Accessed September 29, 2006.
19. Lugada ES, Mermin J, Kaharuza F, et al. Population-based hematological and immunological reference values for a healthy Ugandan population. Clin Diagn Lab Immunol. 2004;11:29-34.
20. Lisse IM, Aaby P, Whittle H, et al. T-lymphocyte subsets in. West African children: impact of age, sex, and season. J Pediatr. 1997;130:77-85.
21. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal singledose nevirapine compared with zidovudine for prevention of mother-tochild transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomized trial. Lancet. 1999;54:795-802.
22. Jackson. JB, Musoke P, Fleming T, et al. Intrapartum and neonatal singledose nevirapine compared with zidovudine for prevention of mother-tochild transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomized trial. Lancet. 2003;362:859-868.
23. Zheng Y, Heagerty PJ. Partly conditional survival models for longitudinal data. Biometrics. 2005;61:379-391.
24. Heagerty PJ, Lumley T, Pepe MS. Time dependant ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56: 337-344.
25. HIV Pediatric Prognostic Markers Collaborative Study. Use of total lymphocyte count for informing when to start antiretroviral therapy in HIV-infected children: a meta-analysis of longitudinal data. Lancet. 2005; 366:1868-1874.
26. Rouet F, Inwoley A, Ekouevi DK, et al. CD4 percentages and total lymphocyte counts as early surrogate markers for pediatric HIV-1 infection in resource-limited settings. J Trop Pediatr. 2006;52:346-354.
27. Rich KC, Fowler MG, Mofenson LM, et al. Maternal and infant factors predicting disease progression in human immunodeficiency virus type 1-infected infants. Pediatrics. 2000;105:e8.
28. HIV Pediatric Prognostic Markers Collaborative Study Group. Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet. 2003;362:1605-1611.
29. Violari A, Cotton M, Gibb D, et al. Antiretroviral therapy initiated before 12 weeks of age reduced early mortality in young HIV infected infants: evidence from the Children with HIV Early Antiretroviral Therapy (CHER) Study. Presented at: the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 25, 2007; Sydney, Australia. Abstract WESS103.
30. Taha TE, Graham SM, Kumwenda NI, et al. Morbidity among human immunodeficiency virus-1-infected and -uninfected African children. Pediatrics. 2000;106:e77.
31. Gibb D, Duong T, 3Cs4kids Cohort Collaboration. Markers for predicting mortality in HIV infected children in resource-limited settings. AIDS. 2008;22(1):97-105.
32. van der Ryst E, Kotze M, Joubert G, et al. Correlation among total lymphocyte count, absolute CD4+ count, and CD4+ percentage in a group of HIV-1-infected South African patients. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;19:238-244.